In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.
Cancer Network Editors
Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.
Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.
Do you know how many new cases of ovarian cancer are expected in 2018? And could long-term oral contraceptive use be a chemopreventive for certain gynecologic cancers? Test your knowledge in our latest quiz.
Do you know what dose of carfilzomib is associated with an increased incidence of cardiovascular events in multiple myeloma patients? How about the estimated incidence of new myeloma cases in 2018? Test your knowledge in our latest quiz.
Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.
In this slide show we highlight some of the top news on lung cancer in 2017, including FDA approvals, a new standard of care for ALK-positive lung cancer, increased risk with vitamin B supplements, and more.
In this slide show we highlight some of the top news on breast cancer in 2017, including long-term benefits of mammography, treatment advances, pregnancy in survivors, and more.
In this slide show we highlight some of the top news on hematologic cancers in 2017, including effective therapies for pediatric hematologic malignancies, a variety of FDA approvals, new discoveries in myeloma, and more.
In this slide show we highlight some of the top news on gynecologic cancers in 2017, including studies on surgery for cervical and ovarian cancer, the FDA approval of niraparib, and more.